Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase

Medical and Pediatric Oncology

Volumn 38, Issue 5, 2002, Pages 310-316

  Albertsen, Birgitte Klug ^a   Schrøder, Henrik ^b   Jakobsen, Preben ^b   Avramis, Vassilios I ^c   Müller, Hans Joachim ^d   Schmiegelow, Kjeld ^e   Carlsen, Niels T ^f  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e Rigshospitalet   (Denmark)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Asparaginase antibodies; Asparaginase pharmacokinetics; Childhood acute lymphoblastic leukemia; Erwinia asparaginase

Indexed keywords

ASPARAGINASE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AMINO ACID ANALYSIS; ANTIBODY RESPONSE; ARTICLE; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; DRUG MONITORING; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL;

ADOLESCENT; ANTIBODY FORMATION; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERWINIA; FEMALE; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; PROSPECTIVE STUDIES;

EID: 0036255941     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10096     Document Type: Article

References (17)

1. Asparagine synthetase activity in paediatric acute leukemias: AML-M5 subtype shows lowest activity
2. L-asparaginase-pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans
3. L-asparaginase, clinical, biochemical, pharmacological, and immunological studies
4. Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia culture
5. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia
6. Methotrexate/L-asparaginase combination chemotherapy for patients with acute leukemia in relapse: A study of 36 children
7. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma
8. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia
9. Anaphylaxis to L-aspara-ginase during treatment for acute lymphoblastic leukemia in children - Evidence of a complement-mediated mechanism
10. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement
11. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia
12. Systemic allergic reactions in children with acute lymphoblastic leukemia undergoing a second exposure to Erwinia C. L-asparaginase may occur more frequently if the drug is given intravenously
13. Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration
14. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations
15. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia
16. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia
17. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia